Large gap with delayed quotes
|
Last quote
10/17/2026
-
02:00:00
|
Bid
10/16/2026 -
21:59:56
|
Bid Volume |
Ask
10/16/2026 -
21:59:56
|
Ask Volume |
|---|---|---|---|---|
|
9.55
-0.71
(
-6.92% )
|
9.53
|
5,900 |
9.54
|
900 |
Analysis date: 13.10.2026
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 06.10.2026.
Quality
Very weak
Very weak
One star since 31.07.2026.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 06.03.2026 at a price of 18.15.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 31.07.2026.
4wk Rel Perf
-18.73%
-18.73%
The four-week dividend-adjusted underperformance versus SP500 is 18.73%.
Risk
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.15%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.60%.
Mkt Cap in $bn
0.91
0.91
With a market capitalization <$2bn, MOONLAKE IMMUNOTHERAPEUTICS is considered a small-cap stock.
G/PE Ratio
1.48
1.48
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
-9.58
-9.58
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
14.12%
14.12%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
10
10
Over the last seven weeks, an average of 10 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
93
93
For 1% of index variation, the stock varies on average by 0.93%.
Correlation
0.13
0.13
Stock movements are totally independent of index variations.
Value at Risk
3.28
3.28
The value at risk is estimated at USD 3.28. The risk is therefore 31.49%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025